VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial
A prescription medicine for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
MENU

Questions? Call 1-833-VYV-CIDP (1-833-898-2437)

A prescription medicine for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
STAY UP TO DATE

Questions? Call 1-833-VYV-CIDP (1-833-898-2437)

NOW APPROVED—VYVGART Hytrulo prefilled syringe for self‑injection
(Subcutaneous injection: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase)

Sign up here to learn more.

Bustin’ a move when the moment’s right.

that’s living VYVIDLY™

What does it mean to live VYVIDLY with CIDP? Find out more about this FDA-approved treatment below.

STAY UP TO DATE

CIDP=chronic inflammatory demyelinating polyneuropathy

Call 1-844-674-3504 for more information on the CIDP Ambassador Program

A different approach to CIDP

VYVGART Hytrulo works differently than other chronic inflammatory demyelinating polyneuropathy (CIDP) treatments, including IVIg, SCIg, PLEX, and steroids.

speaker

The first major innovation in CIDP treatment in over 30 years.*

droplet crossed out

The first and only plasma-free treatment approved by the FDA for CIDP.

flying clock

A first for CIDP—one weekly injection, given under the skin by a healthcare professional, that takes ~30 to 90 seconds.†

*VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.
†After administering your injection, your healthcare provider will monitor you for allergic reactions for at least 30 minutes.
FcRn=neonatal Fc receptor; IVIg=intravenous immunoglobulin; PLEX=plasma exchange; SCIg=subcutaneous immunoglobulin

About the VYVGART Hytrulo clinical study

document with magnifying glass

Learn about the effectiveness and safety of VYVGART Hytrulo—established in the largest clinical study in CIDP history

reduced risk

See how the VYVGART Hytrulo study measured the reduced risk of arm and leg symptoms getting worse

99%

of eligible patients chose to be part of an extended safety study and receive VYVGART Hytrulo (226 out of 228 patients)

A couple is driving together
A couple is driving together
CIDP treatment that lets you help call the shots.

that’s living VYVIDLY

NOW APPROVED—VYVGART Hytrulo prefilled syringe for self-injection (Subcutaneous injection: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase).

Download these quick facts to learn more, and sign up for updates.

STAY INFORMED
discussion guide image discussion guide image discussion guide image

Share your CIDP experience with your neurologist

The CIDP Doctor Discussion Guide is an easy-to-use tool that can help you track your CIDP symptoms and abilities. Providing a better understanding of your daily life with CIDP may help your doctor determine if VYVGART Hytrulo is right for you.

DOWNLOAD THE
DISCUSSION GUIDE
Icon_Patient_Caregiver_Heart@2x

Share your story

Your story is special because it is yours to tell. Sign up for the CIDP Patient Ambassador Program so you can make your mark on the CIDP community by sharing your personal experience living with or caring for someone with CIDP.

Make a difference and join us to inspire others. Learn more about the Patient Ambassador Program by calling us at 1-844-674-3504 or email amalia@mypatientstory.com.

My PRODUCT Y Path

Personalized support for every step of your VYVGART Hytrulo journey

After your doctor has prescribed you VYVGART Hytrulo, you can enroll in My VYVGART Path. Once enrolled, a Nurse Case Manager can assist you with tracking your symptoms and abilities to help prepare you for conversations with your doctor.

LEARN MORE
Live VYVIDLY Logo
Live VYVIDLY Logo

Have questions? Call 1-833-VYV-CIDP (1-833-898-2437) to speak with an educator about CIDP, how VYVGART Hytrulo works, study data, cost and coverage, and more.

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • hives
    • trouble breathing
    • low blood pressure
    • fainting
  • Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO.

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • hives
    • trouble breathing
    • low blood pressure
    • fainting
  • Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO.

Questions? Call 1-833-VYV-CIDP
(1-833-898-2437)

This site is intended for patients and caregivers.

Disclaimer | Privacy Policy | Contact Us |

Patient and Prescribing Information
VYVGART Hytrulo Patient Information VYVGART Hytrulo Prescribing Information VYVGART Hytrulo Prefilled Syringe Instructions for Use

VYVGART is a registered trademark of argenx.

VYVGART Hytrulo is a trademark of argenx.

LIVE VYVIDLY is a trademark of argenx.

LIVING VYVIDLY is a trademark of argenx.

For U.S. audiences only.

©2025 argenx 

US-VYV_HYT-25-00072 V1 04/2025

argenx logo